A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248

Gastrointestinal Stromal Tumor

Approved for marketing

3

Start Date 09/01/2004

Age of Trial (yrs) 20.2

Gleevec-resistant

KIT/PDGFRA inhibitor

Block KIT

Specifically GIST and only GIST

A6181036

Pfizer

Pfizer Oncology Clinical Trial Information Service

1-877-369-9753

Oral

This treatment use trial is still available to GIST patients in some countries where Sutent is not yet approved. Contact the Pfizer Oncology Clinical Trial Information Service for information on trial sites. Also use the NCT# link to see the trial details in clinicaltrials.gov.
Sutent is approved in many countries for Gleevec-resistant GIST. This trial provides access to patients in countries where it is not approved.

AS of 11/23/09 two sites in India were recruiting.